Finerenone (BAY 94-8862) PEG solution + Finerenone (BAY 94-8862) immediate release tablet + Eplerenone (Inspra®) + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clinical Pharmacology
Conditions
Clinical Pharmacology
Trial Timeline
Mar 29, 2010 → May 17, 2011
NCT ID
NCT01473108About Finerenone (BAY 94-8862) PEG solution + Finerenone (BAY 94-8862) immediate release tablet + Eplerenone (Inspra®) + Placebo
Finerenone (BAY 94-8862) PEG solution + Finerenone (BAY 94-8862) immediate release tablet + Eplerenone (Inspra®) + Placebo is a phase 1 stage product being developed by Bayer for Clinical Pharmacology. The current trial status is completed. This product is registered under clinical trial identifier NCT01473108. Target conditions include Clinical Pharmacology.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01473108 | Phase 1 | Completed |
Competing Products
20 competing products in Clinical Pharmacology